Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from SSY Group ( (HK:2005) ) is now available.
SSY Group Limited has announced that its Drotaverine Hydrochloride, an antispasmodic drug used for treating spasms in the biliary, urinary, and gastrointestinal tracts, has received approval for registration from the National Medical Products Administration of China. This development marks a significant step for the company in expanding its product offerings and strengthening its position in the pharmaceutical market, potentially benefiting shareholders and investors.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
More about SSY Group
SSY Group Limited operates in the pharmaceutical industry, focusing on the development and production of medical drugs. The company specializes in creating bulk drugs and has a market focus on antispasmodic medications, among others.
Average Trading Volume: 14,685,422
Technical Sentiment Signal: Sell
Current Market Cap: HK$9.09B
See more insights into 2005 stock on TipRanks’ Stock Analysis page.